- Home
- NBTX vs KYTX Comparison
NBTX vs KYTX Comparison
Compare NBTX & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- KYTX
- Stock Information
- Founded
- NBTX 2003
- KYTX 2018
- Country
- NBTX France
- KYTX United States
- Employees
- NBTX N/A
- KYTX N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- KYTX
- Sector
- NBTX Health Care
- KYTX
- Exchange
- NBTX Nasdaq
- KYTX NYSE
- Market Cap
- NBTX 201.9M
- KYTX 242.1M
- IPO Year
- NBTX 2020
- KYTX 2024
- Fundamental
- Price
- NBTX $3.83
- KYTX $3.99
- Analyst Decision
- NBTX Strong Buy
- KYTX Buy
- Analyst Count
- NBTX 2
- KYTX 5
- Target Price
- NBTX $11.50
- KYTX $23.20
- AVG Volume (30 Days)
- NBTX 8.8K
- KYTX 248.8K
- Earning Date
- NBTX 11-26-2024
- KYTX 11-13-2024
- Dividend Yield
- NBTX N/A
- KYTX N/A
- EPS Growth
- NBTX N/A
- KYTX N/A
- EPS
- NBTX N/A
- KYTX N/A
- Revenue
- NBTX $45,220,186.00
- KYTX N/A
- Revenue This Year
- NBTX N/A
- KYTX N/A
- Revenue Next Year
- NBTX N/A
- KYTX N/A
- P/E Ratio
- NBTX N/A
- KYTX N/A
- Revenue Growth
- NBTX 526.17
- KYTX N/A
- 52 Week Low
- NBTX $3.57
- KYTX $3.94
- 52 Week High
- NBTX $8.96
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- NBTX 38.67
- KYTX 30.54
- Support Level
- NBTX $3.57
- KYTX $3.94
- Resistance Level
- NBTX $4.11
- KYTX $4.34
- Average True Range (ATR)
- NBTX 0.28
- KYTX 0.38
- MACD
- NBTX -0.00
- KYTX -0.10
- Stochastic Oscillator
- NBTX 26.31
- KYTX 2.99
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.